Joint Meeting of the Anti-Infective Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee; Amendment of Notice, 70518 [E6-20538]
Download as PDF
<![CDATA[
70518
Federal Register / Vol. 71, No. 233 / Tuesday, December 5, 2006 / Notices
other than their time. The total
estimated annual burden hours are 300.
Estimated Annualized Burden Hours
Number of
respondents
Respondents
Participant Solicitation Telephone Screening Questionnaire ......................................................
Household Survey Questionnaire ................................................................................................
Dated: November 28, 2006.
Joan F. Karr,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. E6–20539 Filed 12–4–06; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Joint Meeting of the Anti-Infective
Drugs Advisory Committee and the
Drug Safety and Risk Management
Advisory Committee; Amendment of
Notice
AGENCY:
Food and Drug Administration,
HHS.
ycherry on PROD1PC64 with NOTICES
ACTION:
Notice.
The Food and Drug Administration
(FDA) is announcing an amendment to
the notice of joint meeting of the AntiInfective Drugs Advisory Committee
and the Drug Safety and Risk
Management Advisory Committee. This
meeting was announced in the Federal
Register of November 15, 2006 (71 FR
66545). The amendment is being made
to reflect a change in the Location
portion of the document. There are no
other changes.
FOR FURTHER INFORMATION CONTACT:
Sohail Mosaddegh, Center for Drug
Evaluation and Research (HFD–21),
Food and Drug Administration, 5600
Fishers Lane (for express delivery, 5630
Fishers Lane, rm. 1093) Rockville, MD
20857, 301–827–7001, fax: 301–827–
6776, e-mail:
sohail.mosaddegh@fda.hhs.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington DC area), codes 301–451–
2530 or 301–451–2535. Please call the
Information Line for up-to-date
information on this meeting.
SUPPLEMENTARY INFORMATION: In the
Federal Register of November 15, 2006,
FDA announced that a joint meeting of
Anti-Infective Drugs Advisory
Committee and the Drug Safety and Risk
Management Advisory Committee
would be held on December 14 and 15,
2006. On page 66545, in the first
column, the Location portion of
document is amended to read as
follows:
Location: Hilton, Maryland
Ballrooms, 8727 Colesville Road, Silver
Spring, MD. The hotel phone number is
301–589–5200.
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14,
relating to the advisory committees.
Dated: November 29, 2006.
Randall W. Lutter,
Associate Commissioner for Policy and
Planning.
[FR Doc. E6–20538 Filed 12–5–06; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Health Resources
and Services Administration (HRSA)
publishes abstracts of information
collection requests under review by the
Office of Management and Budget
(OMB), in compliance with the
Paperwork Reduction Act of 1995 (44
U.S.C. Chapter 35). To request a copy of
the clearance requests submitted to
OMB for review, call the HRSA Reports
Clearance Office on (301) 443–1129.
The following request has been
submitted to the Office of Management
and Budget for review under the
Paperwork Reduction Act of 1995:
Number of
respondents
Form
AENT ....................................................................................
VerDate Aug<31>2005
15:14 Dec 04, 2006
Jkt 211001
PO 00000
Frm 00018
Responses
per
respondent
500
Fmt 4703
Sfmt 4703
Number of
responses per
respondent
1200
600
1
1
Average
burden per
response
(in hours)
5/60
20/60
Proposed Project: Advanced Education
Nursing Traineeship (AENT) and Nurse
Anesthetist Traineeship (NAT): In Use
Without Approval
The Health Resources and Services
and Administration (HRSA) provides
training grants to educational
institutions to increase the numbers of
advanced education nurses through the
Advanced Education Nursing
Traineeship (AENT) program and the
Nurse Anesthetist Traineeship (NAT)
program.
HRSA developed the AENT and NAT
tables for the guidance applications for
the two nursing traineeship programs.
The AENT and NAT tables are used
annually by grant applicants that are
applying for AENT and NAT funding.
The funds appropriated for the AENT
and NAT programs are distributed
among eligible institutions based on a
formula. Award amounts are based on
enrollment and graduate data reported
on the tables and two funding factors
(Statutory Funding Preference and
Statutory Special Consideration) to
those institutions which the criteria for
one or both of the funding factors.
The AENT/NAT tables include
information on program participants
such as the number of enrollees, number
of graduates and the types of programs
they are enrolling into and/or from
which they are graduating. These tables
will be available electronically through
Grants.gov. AENT and NAT applicants
will have a single access point to submit
their grant applications and AENT/NAT
Traineeship tables.
Data from the tables will be used in
the award determination and validation
process. Additionally, the data will be
used to ensure programmatic
compliance, report to Congress and
policymakers on the program
accomplishments, and formulate and
justify future budgets for these activities
submitted to OMB and Congress.
The burden estimate for this project is
as follows:
Total
responses
1
E:\FR\FM\05DEN1.SGM
500
05DEN1
Hours per
response
Total burden
hours
1
500
]]>Agencies
[Federal Register Volume 71, Number 233 (Tuesday, December 5, 2006)]
[Notices]
[Page 70518]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-20538]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Joint Meeting of the Anti-Infective Drugs Advisory Committee and
the Drug Safety and Risk Management Advisory Committee; Amendment of
Notice
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
The Food and Drug Administration (FDA) is announcing an amendment
to the notice of joint meeting of the Anti-Infective Drugs Advisory
Committee and the Drug Safety and Risk Management Advisory Committee.
This meeting was announced in the Federal Register of November 15, 2006
(71 FR 66545). The amendment is being made to reflect a change in the
Location portion of the document. There are no other changes.
FOR FURTHER INFORMATION CONTACT: Sohail Mosaddegh, Center for Drug
Evaluation and Research (HFD-21), Food and Drug Administration, 5600
Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093)
Rockville, MD 20857, 301-827-7001, fax: 301-827-6776, e-mail:
sohail.mosaddegh@fda.hhs.gov, or FDA Advisory Committee Information
Line, 1-800-741-8138 (301-443-0572 in the Washington DC area), codes
301-451-2530 or 301-451-2535. Please call the Information Line for up-
to-date information on this meeting.
SUPPLEMENTARY INFORMATION: In the Federal Register of November 15,
2006, FDA announced that a joint meeting of Anti-Infective Drugs
Advisory Committee and the Drug Safety and Risk Management Advisory
Committee would be held on December 14 and 15, 2006. On page 66545, in
the first column, the Location portion of document is amended to read
as follows:
Location: Hilton, Maryland Ballrooms, 8727 Colesville Road, Silver
Spring, MD. The hotel phone number is 301-589-5200.
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.
Dated: November 29, 2006.
Randall W. Lutter,
Associate Commissioner for Policy and Planning.
[FR Doc. E6-20538 Filed 12-5-06; 8:45 am]
BILLING CODE 4160-01-S
